The status of this drug is unclear, as Tanox is negotiating how to proceed with Novartis and Genentech.

FORBES: Attacking Asthma, For A Price

Tanox was developing promising drugs for macular degeneration and asthma.

FORBES: Genentech's Next Act

The two collaborators and a third partner, tiny Tanox (nasdaq: TNOX - news - people ) of Houston, recently submitted additional clinical trial results on thousands of patients that they say should satisfy U.S. regulators' demands for more data to confirm the drug is safe.

FORBES: Attacking Asthma, For A Price